The global drug device combination market is expected to reach $17.7 billion by 2024, according to a new report from Grand View Research. The report points to minimally invasive alternatives like transdermal patches as high-impact growth drivers in the industry. As researchers develop these products, regulatory agencies have taken notice and the report notes that […]
Motion-directed microrobots for targeted drug delivery
Researchers have created tiny ‘microbots’ that are able to move and react in a fashion similar to bacteria, according to a report from the Max Planck Institute for Intelligent Systems. Bacteria use flagella to move, directed by stimuli like sources of light or the earth’s magnetic field. Researchers have developed synthetic microrobots with motility and phototaxis, […]
Enable Injections lands $30m Series A for large-volume injector
Enable Injections Inc. said today that it closed a $30 million Series A round to bring its large-volume injector to market. The Cincinnati, Ohio-based company’s Enable Injector adheres to a patient’s body and delivers biologic doses as large as 50 milliliters. It can be used at work or at home, providing an alternative to costly […]
Nobel chemistry prize goes to molecular machinery
A group of European scientists won the 2016 Nobel Prize for chemistry for developing the “world’s smallest machines,” which could be used to revolutionize drug delivery. Jean-Pierre Sauvage, J. Fraser Stoddart and Bernard Feringer claimed the $931,000 prize (8 million Swedish crowns) for work that Feringer described as having “endless” potential, according to Reuters. “Think of a […]
QuiO raises $1m for smart injection device
QuiO said last week that it closed a $1.05 million seed round led by undisclosed investors to finish developing its smart injection device, prep for pilot studies and an FDA 510(k) submission. The New York-based company is developing a smart injection device and software to monitor patient adherence to clinical trial and daily regimens. Average […]
Self-selecting peptides hold promise for drug delivery
Researchers developed self-selecting polymers that form by adapting to their environment, according to a study published yesterday in Nature Nanotechnology. The peptides continually reorganize their sequences to form polymers most suited to their environment, instead of researchers designing polymers to fit their surroundings or relying on chance discovery. “In our quest to find materials based on […]
Committee pens letter to Mylan demanding EpiPen price info
Members of the U.S. House Committee on Oversight & Government Reform penned a letter to Mylan (NSDQ:MYL) demanding a more complete look at the pricing of its EpiPen epinephrine auto-injector. At a Sept. 21 congressional hearing, Mylan CEO Heather Bresch testified that the company makes a $100 profit per 2-pack of EpiPens. Last week, Mylan […]
Hospital researchers explore MRI for drug delivery
Researchers have programmed an MRI scanner to simultaneously monitor magnetized particles while propelling them through blood vessels as a means to locally deliver drugs. Existing approaches combine the magnetic force from an MRI scanner with the force produced by particle collisions. But traditionally, it’s challenging to image using the MRI scanner and propel the particles […]
Analyst: Insulet’s drug-delivery biz a long-term growth driver
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to […]
Dicerna bails on EnCore lipid nanoparticle tumor delivery program
Dicerna Pharmaceuticals (NSDQ:DRNA) said yesterday that it plans to spike the development program for its lipid nanoparticle delivery system for solid tumors because its preliminary results don’t meet expectations. The Cambridge, Mass.-based company evaluated its lipid nanoparticle, DCR-MYC, in a pair of clinical trials – a Phase I study of patients with solid tumors, hematological […]